Dr. Jin Wang
CEO of Tolo Biotech, China
Title: CRISPR/Cas12-based Next-Generation Diagnostics
Abstract:
CRISPR diagnostic
technology is well-known as the "next generation diagnostic
technology" due to its advantages of specificity, sensitivity, and
simplicity. Up to date, merely two types of Cas proteins (i.e. Cas12 and Cas13) are found to possess the
trans-cleavage activities, which nonspecifically cleave non-target
single-stranded nucleic acids and can be employed for the development of
next-generation CRISPR diagnostic systems. Our group first characterized the
Cas12 ssDNA trans-cleavage activities and then created the HOLMES system for
rapid nucleic acid detection. So far, HOLMES has been used in many scenarios of
rapid nucleic acid detection. Here, I will give examples on the applications of
HOLMES in rapid detection of non-nucleic acid targets.
Keywords: CRISPR, Cas12, trans-cleavage activity, HOLMES,
non-nucleic acid detection
Biography:
Jin Wang, Ph.D., CEO of ToloBio and Professor of the First Affiliated
Hospital of Shenzhen University. Dr. Wang obtained his PhD in microbiology from
the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
and subsequently completed his postdoctoral research in microbiology at the
Chinese University of Hong Kong. Now, he is focusing on the development and applications of the CRISPR-based
next-generation molecular diagnostic technologies and is also a recipient of the National Science Fund for the National Distinguished
Young Scholars in China. In 2017, his group
first discovered the ssDNA trans-cleavage activities of CRISPR/Cas12 protein,
and subsequently developed the HOLMES rapid nuleic acid detection system. In
2020 and 2021, he promoted the exclusive patent cross-licensing collaboration
between ToloBio and Sherlock Bio. In the future, he and his group are willing
collaborate with IVD fellows to promote the industrialization of the CRISPR
diagnostic technologies.